Chimeric antigen receptor (CAR) T cells in the solid tumor microenvironment enter a partially dysfunctional state called T cell exhaustion. Interleukin (IL)-10-producing CAR T cells retain their metabolic fitness, resist T cell exhaustion and display unprecedented antitumor activity indicated by high cure rates and durable responses in mice. Clinical studies of IL-10-producing CAR T cells are underway.